VisualSonics Launches Revolutionary Imaging Technology to Advance Cancer Research: The Vevo LAZR Photoacoustics Imaging System
March 24 2011 - 6:30AM
Business Wire
VisualSonics Inc., a leader in real-time, in vivo,
high-resolution micro-imaging systems and a wholly-owned subsidiary
of SonoSite Inc., (Nasdaq:Sono), today announced the
launch of the Vevo® LAZR Photoacoustics Imaging system for the
advancement of cancer research in the pre-clinical imaging market.
This revolutionary technology combines the sensitivity of optical
imaging with the resolution and depth penetration of high-frequency
ultrasound, enabling researchers to study cancer in its earliest
stages of progression and detect and evaluate tumor growth. For the
first time, researchers will be able to observe tumor biology,
measure hypoxia (oxygen levels), evaluate changes in blood flow,
and quantify data with unique software solutions in vivo and in
real-time. Ultimately, this technology provides researchers with
never-before-seen insights into the development of effective
therapeutics for treating cancer. The Vevo LAZR photoacoustics
system will debut at the American Association of Cancer Research on
April 3-6th at the Orange County Convention Center, Orlando,
Florida.
After two years of research and development, images and data
generated by the Vevo LAZR system were presented at the World
Molecular Imaging Conference (WMIC) in Kyoto, Japan in September
2010, where the system received strong feedback from prestigious
organizations and research institutes from around the globe. One of
the first scientific users of the Vevo LAZR system, David A.
Jaffray, Ph.D., Head, Radiation Physics - Ontario Cancer Institute
/ Princess Margaret Hospital, commented, “Advanced imaging
technologies like VisualSonics’ Vevo LAZR photoacoustics
system allow our scientists to see into the processes that sustain
a disease like cancer. With this knowledge, we can design the next
generation of therapies.”
“The Vevo LAZR photoacoustics system is the future of
pre-clinical research,” said Anil Amlani, VisualSonics’ President
and CEO. “Building on our high-frequency ultrasound technology,
which is now considered a gold standard for many in vivo
applications, the Vevo LAZR photoacoustics system offers the unique
capability to non-invasively capture real-time, high-resolution
data that is unavailable and unparalleled to any other in vivo
anatomical or molecular imaging technology.”
The platform of the Vevo LAZR system integrates proprietary
imaging capabilities that will further improve a researcher’s
overall experience and will set new standards for performance in
pre-clinical research. The system’s co-registration function is an
essential feature that will aid in the discovery and assessment of
novel drug therapies. With the ability to capture high-resolution
images with high-frequency ultrasound, the co-registration function
enables researchers to simultaneously superimpose a photoacoustic
signal over the ultrasound image, allowing for the assessment and
quantification of oxygen saturation and blood levels in tissues and
organs. The Vevo LAZR system also includes an automated
multispectral imaging algorithm that provides researchers with the
flexibility of selecting multiple imaging wavelengths to optimize
the visualization of contrast agents, such as nanoparticles and
dyes.
Mr. Amlani continued, “We believe the Vevo LAZR system will have
a strong impact on the discovery of new cancer therapies in the
pre-clinical market space and that we will see a translation of
these discoveries into practical applications in humans. With a
healthy set of pre-ordered systems, we are anticipating strong
product demand.”
“The launch of this ‘new to the world’ technology keeps
VisualSonics at the forefront of imaging advancements for
life-sciences research,” said Kevin M. Goodwin, SonoSite President
and CEO. “We are excited that SonoSite and VisualSonics have joined
forces to innovate and deliver new breakthrough imaging
technologies and we are pleased with the initial customer demand
for the new product.”
The Vevo LAZR system supports VisualSonics’ continuous efforts
to provide researchers with innovative solutions to improving
pre-clinical research. The core of the Vevo LAZR technology is the
LZ® Series integrated fiber-optic linear array transducers with
microbeamforming technology. Harnessing the sensitivity of 256
active elements, the LZ Series transducer provides clear and
high-resolution images - in both 2D and 3D modes. Applications for
the Vevo LAZR system range from lymph node imaging, study of
hemoglobin and oxygen saturation, and targeted imaging of tumor
biomarkers. In addition to cancer biology, this cutting-edge
imaging system will benefit other areas of research such as
diabetes, neurosciences, as well as developmental and reproductive
biology.
Researchers are invited to experience a demonstration of the
Vevo LAZR system by visiting VisualSonics at booth #2171 at
AACR.
About VisualSonics
VisualSonics is the world leader in real-time, in vivo,
high-resolution micro-imaging systems designed specifically for
preclinical research and a wholly-owned subsidiary of SonoSite,
Inc. (Nasdaq:Sono). The Company’s cutting-edge technologies
allow researchers at the world’s most prestigious pharmaceutical
and biotechnology companies, hospitals and universities to conduct
research in cardiovascular, cancer, neurobiology and developmental
biology areas. The micro-imaging technologies support research
applications that include genetic research, phenotypic studies and
drug development. VisualSonics micro-imaging platforms combine
high-resolution, real-time in vivo imaging at reasonable cost with
ease-of-use and quantifiable results.
About SonoSite
SonoSite, Inc. (www.sonosite.com) is the innovator and world
leader in bedside and point-of-care ultrasound and an industry
leader in ultra high-frequency micro-ultrasound technology and
impedance cardiography equipment. Headquartered near Seattle, the
company is represented by fourteen subsidiaries and a global
distribution network in over 100 countries. SonoSite’s small,
lightweight systems are expanding the use of ultrasound across the
clinical spectrum by cost-effectively bringing high-performance
ultrasound to the point of patient care.
Forward-looking Information and the
Private Litigation Reform Act of 1995
Certain statements in this press release relating to the
expected benefits of the Vevo LAZR Photoacoustics Imaging
technology, including market acceptance of products incorporating
Vevo LAZR Photoacoustics Imaging technology and new market and
sales opportunities for SonoSite, and other statements regarding
future results are “forward-looking statements” for the purposes of
the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. These forward-looking statements are based on
the opinions and estimates of our management at the time the
statements are made and are subject to risks and uncertainties that
could cause actual results to differ materially from those expected
or implied by the forward-looking statements. These statements are
not guaranties of future performance and are subject to known and
unknown risks and uncertainties and are based on potentially
inaccurate assumptions. Factors that could cause actual results to
differ from the forward-looking statements include: the risk that
the technology will not yield the expected potential benefits,
including the risk that we are unsuccessful in achieving market
acceptance of this technology, and the potential
for competitive technologies, as well as other factors
contained in the Item 1A. “Risk Factors” section of SonoSite,
Inc.’s most recent Annual Report on Form 10-K filed with the
Securities and Exchange Commission. We caution readers not to place
undue reliance upon these forward-looking statements that speak
only as to the date of this release. We undertake no obligation to
publicly revise any forward-looking statements to reflect new
information, events or circumstances after the date of this release
or to reflect the occurrence of unanticipated even.
Sonos (NASDAQ:SONO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Sonos (NASDAQ:SONO)
Historical Stock Chart
From Jul 2023 to Jul 2024